LA
Therapeutic Areas
Longeveron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Laromestrocel (Lomecel-B™) | Hypoplastic Left Heart Syndrome (HLHS) | Phase 2b |
Leadership Team at Longeveron
WH
Wa'el Hashad
Chief Executive Officer
CM
Chris Min, M.D., Ph.D.
Chief Medical Officer
JH
Joshua Hare, M.D.
Co-founder, Chief Science Officer, Chairman
JB
Jerome Bailey
Vice President of Business Operations
RK
Richard Kender
Board Member
UU
Ursula Ungaro
Board Member